VIVXF (Avivagen) Total Stockholders Equity: $-7.01 Mil (As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avivagen Total Stockholders Equity?

Avivagen VIVXF -99.00% Total Stockholders Equity is $-7.01 Mil as of Jul. 2023.

Avivagen's Total Stockholders Equity for the quarter that ended in Jul. 2023 was $-7.01 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Avivagen's Book Value per Share for the quarter that ended in Jul. 2023 was $-0.09. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Avivagen's Debt-to-Equity for the quarter that ended in Jul. 2023 was -0.78.

Avivagen  (OTCPK:VIVXF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Avivagen's Book Value per Share for the quarter that ended in Jul. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-7.013-0)/77.695
=-0.09

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Avivagen's Debt-to-Equity for the quarter that ended in Jul. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.646 + 0.834) / -7.013
=-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Total Stockholders Equity Related Terms

Avivagen Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Avivagen's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Total Stockholders Equity Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 -2.47 -3.61 -3.18 -4.37

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.07 -4.37 -5.30 -6.16 -7.01
What does a Total Stockholders Equity of $-7.01 Mil mean?
Avivagen (VIVXF) has a Total Stockholders Equity of $-7.01 Mil as of Jul. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Avivagen and its competitors.
Is Avivagen's Total Stockholders Equity too high?
Avivagen's current Total Stockholders Equity is $-7.01 Mil.
How does Avivagen's Total Stockholders Equity compare to DMKPQ and MJNE?
Avivagen's Total Stockholders Equity of $-7.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Avivagen and its competitors. Avivagen's current Total Stockholders Equity is $-7.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Total Stockholders Equity of $-7.01 Mil. The current Total Stockholders Equity is $-7.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Avivagen (VIVXF), the current Total Stockholders Equity is $-7.01 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.